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Zidovudine (AZT) mucoadhesive solid dispersions (SD) were prepared using a sodium starch glycolate 
(SSG) and hypromellose phthalate (HPMCP) mixtures as carrier to enhance the intestinal permeability 
and bioavailability of zidovudine. SDs were prepared using the co-precipitation method followed by 
solvent evaporation and characterized according to their physicochemical properties such as particle size, 
crystallinity, thermal behavior, and liquid uptake ability. In vitro drug dissolution, mucoadhesiveness 
and AZT intestinal permeability were also determined. Thermal behavior and X-ray diffraction patterns 
demonstrated the amorphous state of AZT in SD systems. The HPMCP polymer restricted the liquid 
uptake ability in the acid medium; however, this property significantly increased with higher pH values. 
SDs allowed drug dissolution to occur in a controlled manner. HPMCP decreased the dissolution rates in 
the acid medium. The mucoadhesiveness of SDs was demonstrated and the permeability of AZT carried 
in solid dispersions was significantly improved. The effect of the SD carrier polymers on blocking efflux 
pump can be an important approach to improve the bioavailability of AZT.
Uniterms: Zidovudine. Solid dispersion. Mucoadhesion. P-glycoprotein. Intestinal permeability.
INTRODUCTION
Initially, advances in drug delivery systems were 
primarily based on the synthesis of functional polymers. 
Currently, the development strategies of these systems 
are strongly influenced by a detailed understanding of the 
underlying biological and molecular principles. With this 
knowledge, more sophisticated drug delivery systems 
have been designed that provide better pharmacokinetics, 
reduced toxicity, more focused drug targeting and 
controlled release of the drug (Grund, Bauer, Fischer, 
2011).
The development of new strategies that overcome 
the low bioavailability of AZT mainly focus on the efflux 
mechanism mediated by P-glycoprotein (P-gp), which 
returns drugs absorbed by the intestinal membrane back to 
the lumen, increasing presystemic metabolism, and these 
strategies must overcome the significant challenges of 
reducing the adverse effects that hinder patient therapeutic 
compliance while improving drug bioavailability (Geocze 
et al., 2010).
Zidovudine (Figure 1a) is the drug of choice for 
the treatment of Human Immunodeficiency Virus (HIV), 
which causes acquired immunodeficiency syndrome 
(AIDS). Zidovudine is a reverse transcriptase inhibitor 
that prevents the replication of the DNA strand from 
RNA through competitive inhibition of deoxynucleotide 
triphosphate, ultimately preventing the extension of 
the tape. Zidovudine needs to be converted into its 
triphosphate form for effective antiviral activity against 
the enzyme reverse transcriptase. For this to occur, 
zidovudine is first phosphorylated by thymidine kinase 
intracellularly and then transformed into diphosphate by 
thymidylate kinase. The triphosphate metabolite interrupts 
viral replication through competitive mechanisms. 
Approximately 40% of the AZT dose is metabolized 
presystemically (Carvalho et al., 2009; Teixeira et al., 
2011). Due to its low bioavailability, oral administration 
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of AZT poses a major challenge to the development of 
new systems for controlled drug release. In addition, it 
is a substrate of various efflux mechanisms present in the 
central nervous system, immune system and intestinal 
epithelium, the latter being directly related to issues of 
drug bioavailability (Varatharajan, Thomas, 2009).
Mucoadhesive systems exploit the interaction 
between formulations containing polymers and the mucus 
layer that covers epithelial surfaces throughout the body. 
Due to their increased retention time and closer contact 
with the absorption site, mucoadhesive systems provide 
a promising approach for improving bioavailability by 
maximizing drug absorption (Carvalho et al., 2013; 
Ivarsson, Wahlgren, 2012; Barbi et al., 2015). 
Solid dispersions (SD) are drug delivery systems 
in which the drugs are dispersed in an amorphous state 
in a hydrophilic polymer matrix. This approach has 
been traditionally used to improve the solubility of 
drugs with poor water solubility. In several drugs, it 
has been demonstrated that modifications of structure, 
solubility properties and drug release profiles can enhance 
bioavailability (Chen et al., 2006; Giri et al., 2012).
The SD preparation technique is a simple and low 
cost approach for preparing polymer matrix systems that 
contain drugs in an amorphous state. Studies investigating 
the influence of these structural changes on biological 
interactions, such as mucoadhesion and permeability of 
highly soluble drugs, have not been evaluated.
The polymer blend is a rational approach for obtaining 
novel materials with specific properties that allow suitable 
drug-release control that favors bioavailability (Carbinatto 
et al., 2012; Soares et al., 2013).
Sodium starch glycolate (SSG) (Figure 1 b) 
is a polymer derived from starch largely used as a 
superdisintegrant in tablet formulations. It is practically 
insoluble in water and possesses high hydration capacity 
with the ability to absorb over 300 times its volume 
(Fransén, Björk, Edsman, 2007). The mucoadhesive 
properties of this polymer have been demonstrated in 
topical films and inhalant interactive mixtures that contain 
SSG (Repka, Mcginity, 2000; 2001). Furthermore, it 
has been reported that SSG can function as a polymeric 
excipient with properties that inhibit the intestinal efflux 
mechanisms of drugs (Takizawa et al., 2013).
Hypromellose phtalate (HPMCP) (Figure 1 c) is an 
enteric polymer largely used to coat solid dosage forms. 
Due to its insolubility in acid medium, HPMCP confers 
gastro-resistance to drugs. In addition, its hydroxyl groups 
interact with the mucosa via secondary non-covalent bonds 
and form hydrogen bonds with the mucus, resulting in its 
mucoadhesive properties (Makhlof, Tozuka, Takeuchi, 
2011).
P-glycoprotein (P-gp) is the major efflux transporter 
protein present in intestinal epithelial cells, particularly in 
the apical membrane. It is responsible for the efflux of a 
wide range of structurally unrelated drugs and xenobiotics 
and causes drugs to flow back into the gut lumen. Studies 
in animals and humans have indicated that P-gp plays a 
major role in limiting drug absorption and consequently 
oral bioavailability (Bansal et al., 2009). 
Thus, there is considerable interest in enhancing oral 
bioavailability by inhibiting P-gp-mediated drug efflux. 
Several studies have demonstrated that P-gp inhibitors 
(e.g., verapamil, VER) can improve the bioavailability 
of a large number of molecules (Werle, 2008; Ling et al., 
2010). Takizawa et al. (2013) demonstrated the effects 
of 20 common pharmaceutical excipients (diluents, 
disintegrants, binders, lubricants and sustained release 
substrate) on the mucosal membrane and how their 
effects differ in regions of the small intestine. The effects 
of these excipients on the membrane permeability of 
5(6)-carboxyfluorescein (5-CF) were examined using 
the in vitro sac method in rat jejunum and ileum. The 
authors found that membrane permeability of sodium 
carboxymethyl starch, low-substituted hydroxypropyl 
cellulose and croscarmellose sodium was significantly 
increased in the jejunum.
However,  such  inh ib i to r s  have  in t r in s i c 
pharmacological activity and, consequently, may cause 
toxic side effects. Moreover, evidence suggests that 
excipients of pharmaceutical formulations may block 
intestinal P-gp function enhancing the permeability of 
FIGURE 1 - Chemical structure of: (a) Zidovudine (AZT); (b) Sodium starch glycolate (SSG); (c) Hypromellose phthalate (HPMCP).
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the intestinal substrate drugs (Shen et al., 2006; Mudra, 
Borchardt, 2010).
The use of polymers for P-gp blockade has been 
extensively reported in the scientific literature. Studies 
have demonstrated that SSG and HPMCP enhance oral 
bioavailability through the inhibition of P-gp (Carreno-
Gomez, Duncan, 2001; Takizawa et al., 2013).
Despite the high solubility of AZT, the mucoadhesive 
SD approach could provide a simple and low cost method 
for preparing systems that could change the biological 
interaction of AZT and improve its bioavailability.
In this study, AZT SDs using SSG and HPMCP as 
polymer carriers were prepared and their mucoadhesiveness 
and intestinal permeability were evaluated. The influence of 
P-gp blockade on drug permeability was also investigated.
MATERIAL AND METHODS
Material
AZT was kindly provided by Fundação para o 
Remédio Popular - FURP, Guarulhos/SP, Brazil. Sodium 
starch glycolate was purchased from Henrifarma (São 
Paulo/SP, Brazil). Hypromellose phthalate and Verapamil 
were obtained from Sigma–Aldrich® (Hamburg, Germany). 
Other reagents were of analytical reagent grade.
Solid dispersions preparation
SDs containing AZT were prepared using co-
precipitation methods followed by solvent evaporation. 
Varying concentrations of SSG and HPMCP (1:10:10 
and 1:15:15; AZT: SSG: HPMCP) were used as carrier 
polymers. AZT and SSG were dissolved in a sufficient 
amount of ethanol, under magnetic stirring (30 min). 
HPMCP previously dissolved in NaOH solution (0.05 M) 
was added to the ethanol solution containing AZT and 
SSG. The mixture was stirred for 15 min. Afterwards, 
the solvent was evaporated using a rotary evaporator 
(Tecnal®, Ourinhos/SP, Brazil) under reduced pressure at 
45 ºC for 3 h. The samples were dried in an oven-drier at 
60 ºC (Marconi MA 035®, Piracicaba/SP - Brazil) until the 
moisture content of the samples was less than 10%. The 
product was manually milled using a mortar. The particles 
were sieved (0.42 mm) and stored in a desiccator. Physical 
mixtures (PM) using the same drug:polymer ratios were 
prepared as the control.
Fourier transform infrared spectroscopy (FTIR)
FTIR spectra were recorded in the 4000–400 cm-1 
range using an FT-IR spectrometer (Shimadzu® 8300, 
Kyoto - Japan). The samples were analyzed using KBr 
pellets. The powders were compressed at a pressure of 8 
tons for 3 min using a hydraulic press (Shimadzu® SSP-
10A, Kyoto - Japan).
Differential scanning calorimetry (DSC)
Thermal analyses were carried out using a DSC 
unit (DSC 1 Stare System, Mettler Toledo®, Zurich, 
Switzerland). Indium and zinc were used to calibrate the 
temperature scale and enthalpic response. Samples (5 
mg) were placed in aluminum pans before heating under 
nitrogen flow (50 mL/min) at a scanning rate of 10 ºC/min 
from 25 to 200 ºC. An empty aluminum pan was used as 
the reference.
X-ray diffraction (DRX)
X-ray powder diffraction was performed at room 
temperature with an X-ray diffractometer (Siemens® 
D5000, Berlin, Germany) using monochromatic Cu-Kα 
radiation (λ = 1.5406 Å) operating at 40 kV and 30 mA. 
Samples were analyzed in the range of 2-60º (2θ) using 
a step size of 0.02º (2θ) and scan step time of 0.05/min.
Liquid uptake ability
The liquid uptake ability was assessed using an 
Enslin device (Cury et al., 2009; Prezotti et al., 2012). An 
accurately weighted mass of SD (0.05 g) was uniformly 
spread on a sintered glass filter. The volume of medium 
absorbed by the samples was measured using a pipette 
at predetermined times (5, 30, 60, 90 and 120 min). Two 
different media were tested: simulated gastric medium 
(0.1N HCl, pH 1.2) and simulated enteric medium 
(phosphate buffer, pH 7.4). Neither of the media contained 
enzymes. The tests were performed in triplicate and 
expressed as the percentage of liquid uptake relative to the 
initial mass of the samples, according to equation (Eq. 1):
  (1)
where m is the initial mass of SD (g); V = volume (mL) 
of medium uptake, % S = percentage of media uptake of 
the samples.
In vitro adhesion test
Mucoadhesion properties were evaluated using a 
texture analyzer (TA.XT plus, Stable Micro Systems, 
L. N. Pedreiro, B. S. F. Cury, M. V. Chaud, M. P. D. Gremião718
Godalming, UK) with 50 N load cell, according to the 
procedure described by Fransén, Björk and Edsman 
(2007). Mucin discs (11 mm diameter) were pre-hydrated 
in simulated enteric medium (phosphate buffer, pH 7.4) 
at 37 ºC for 60 seconds. Immediately after, the discs were 
attached to a metallic sample holder using double-sided 
adhesive tape.
The cylindrical ended probe (10 mm diameter) was 
covered with double-sided adhesive tape containing the 
sample. For this step, the adhesive tape was carefully 
pressed against a flat surface containing the powdered 
sample to create a monolayer of particles. The probe was 
moved downward with a speed of 2.0 mm/s, until contact 
was made with the mucin disc; contact was maintained for 
600 seconds. Afterwards, the probe was raised at 2.0 mm/s. 
The maximum force required to detach the probe from the 
sample could be detected directly using Texture Exponent 
Lite software. The total amount of force involved in probe 
withdrawal (Wad - µJ) was determined by calculating the 
area under the force versus distance curve. The tests were 
repeated six times in compression test mode with 2 mN 
of triggered force.
In vitro drug release
In vitro drug release tests were performed using a 
Hanson Dissolution Test Station SR8-Plus (Chatsworth 
- USA) equipped with 150 mL vessels and mini paddles, 
based on the design of apparatus 2 (USP), to mimic system 
hydrodynamics. In vitro drug release was performed in 
simulated gastric medium (0.1N HCl, pH 1.2) for 2 h and 
in simulated enteric medium (phosphate buffer pH 7.4) for 
4 h. The media were kept at 37 °C, while stirring at 50 rpm. 
AZT-free powder served as the control and was also tested.
All samples were put into hard gelatin capsules 
(size 0). The amount of AZT released was quantified 
at predetermined times using a UV spectrophotometer 
(Hewlett Packard 8453, California - USA) with an 
absorption of 267 nm. These tests were performed in 
triplicate under sink conditions.
Intestinal permeability and P-glycoprotein 
influence
The intestinal permeability of AZT was evaluated 
using the everted gut sac model described by Barthe et al. 
(1998a) with modifications purposed by Quevedo et al. 
(2011). The animals were handled in accordance with the 
guide for the care and use of experimental animals (CEUA/
UFSCAR Ethics in Research Committee, nº 003/2011).
Male adult Wistar rats (250-270 g) were kept under 
fasting conditions for 12 h before the assay and then 
anesthetized with sodium thiopental. Immediately after, 
a duodenum segment (approximately 6 cm length) was 
dissected, flushed with TC 199 buffer solution (culture 
medium) at 10 ºC and placed in oxygenated (O2:CO2 – 
95:5) TC 199 buffer of the same temperature. This segment 
was gently inverted with the aid of a flexible cotton 
swab (mini brush, ~2.5 mm diameter). The intestinal 
segment was filled with fresh TC 199 medium and its 
ends were clamped to make a closed sac. The everted 
sac was incubated at 37 ºC in 20 ml of TC 199 with 10 
mM oxygenated (O2:CO2 – 95:5) glucose containing 600 
µg/mL of sample (AZT free powder, SD 1:15:15 or PM 
1:15:15). The assay time was standardized in 90 minutes 
to maintain the viability of the intestinal tissue (Barthe et 
al., 1998b; Barthe, Woodley, Houin, 1999). Afterwards, 
the everted sacs were removed from the incubation 
medium, externally washed with fresh TC 199 and cut 
to obtain the internal content. The content was filtered 
through a cellulose membrane filter (MilliPore 0.45 mm) 
and analyzed using the Varian ProStar® HPLC 330 UV-
VIS PDA spectrophotometric detector and Rheodine VS 
125 (SpectraLab, Toronto – Canada) (Carvalho et al., 
2009). The buffer solution (TC-199, pH 7.4) used in all 
preparations was freshly prepared and had a composition 
of 145 mM NaCl, 4.56 mM KCl, 1.25 mM CaCl2, 5 mM 
NaHPO4 and 10 mM glucose (Correa et al., 2011).
To evaluate the influence of P-gp on AZT 
permeability, the same assay described above was 
performed with the addition of 50 µg/mL of VER added 
to the medium (Quevedo et al., 2011). The tests were 
replicated six times.
Statistical analysis
One-way ANOVA followed by Tukey’s multiple 
comparison procedure was used for statistical analysis 
of the data. A p value less than 0.05 was considered 
statistically significant.
RESULTS AND DISCUSSION
The AZT IR spectrum (Figure 2a) showed three 
characteristic peaks related to the stretching bands of 
the OH group, the C-O of OH groups and C=N=N=N 
(azide group) at 3550–3200 cm-1, 1089 cm-1 and 2083 
cm-1, respectively (Araújo et al., 2003). In the SSG IR 
spectrum (Figure 2 b) peaks assigned to C=C of the 
CH2 group appeared approximately 1640 cm-1 while OH 
stretching bands were observed in the 3550–3200 cm-1 
range. C-O of the ether group was observed in the 1275 
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at 1020 cm-1 range (Puttipipatkhachorn, Pongjanyakul, 
Priprem, 2005). The HPMCP IR spectrum (Figure 2 c) 
revealed absorption bands between 3500 and 3200 cm-1 
reflecting O-H stretching while the peaks related to CH 
(sp3) and C=O of the ester group were observed at 2800 
cm-1 and 1700 cm-1, respectively. The band at 1600 to 
1550 cm-1 was assigned to an aromatic ring and 1000 to 
1200 cm-1 bands were assigned to ether. A peak at 740 
cm-1 was attributed to a monosubstituted aromatic ring 
(Miyazaki et al., 2011). FTIR spectrum analyses were 
performed to identify the characteristic functional groups 
of the polymers and drug. FTIR spectrum analysis was 
also used to evaluate possible interactions between the 
drug and polymer in the SD samples. The characteristic 
peaks of the drug and isolated polymers were recorded. 
The SD and PM IR spectra were similar to those of AZT, 
SSG and HPMCP. The peaks indicated that there were no 
chemical interactions, only physical interactions between 
the components of the system (Araújo et al., 2003).
The DSC data of AZT, SSG, HPMCP, SDs and PMs 
are shown in Figure 3. The AZT thermogram revealed an 
endothermic peak at 126.7 °C, which was related to drug 
melting (Maru et al., 2011), while the SSG and HPMCP 
exhibited a broad endothermic peak in the thermograms 
due to its amorphous nature (Puttipipatkhachorn et al., 
2005). The occurrence of these events is attributed to a 
significant amount of drug in its crystalline state (Cides 
et al., 2006). The absence of any peculiar endothermic 
peaks in the SD thermograms suggests that AZT was 
predominantly in the amorphous form. In addition, the 
absence of these peaks has been attributed to the formation 
of solid drug solution within the polymer matrix (Soares 
et al., 2013).
The diffractograms of AZT, SSG, HPMCP, SDs and 
PMs are shown in Figure 4. AZT diffractograms present 
characteristic peaks approximately 21, 22, 24, 26, 30 and 
32 (2q). The diffraction patterns exhibited by the SDs and 
PMs were similar to the peaks isolated in the polymers 
(SSG and HPMCP). The SD and PM diffractograms 
were an addition of both isolated polymers (SSG and 
HPMCP). The absence of drug-associated peaks in SDs, a 
result of crystalline structure disruption, is consistent with 
FIGURE 3 - DSC of (a) AZT; (b) SSG; (c) HPMCP; (d) SD 
1:10:10; (e) PM 1:10:10; (f) SD 1:15:15; (g) PM 1:15:15.
FIGURE 2 - FT-IR spectra of (a) AZT; (b) SSG; (c) HPMCP; (d) 
SD 1:10:10; (e) PM 1:10:10; (f) SD 1:15:15; (g) PM 1:15:15.
FIGURE 4 - X-ray diffraction patterns of (a) AZT; (b) SSG; (c) 
HPMCP; (d) SD 1:10:10; (e) PM 1:10:10; (f) SD 1:15:15; (g) 
PM 1:15:15.
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the amorphous state of the drug in the solid dispersions 
revealed by the DSC analysis. In PMs, this absence can 
be the result of dilution due to the high proportion of 
polymers in the matrix.
The liquid uptake values (%) of SD, SSG and 
HPMCP in simulated gastric medium are shown in 
Table I. The SSG had the highest values (560.34%) and 
reached equilibrium in a short time (5 min). The %S 
values of SD 1:10:10 and SD 1:15:15 were 395.31% 
and 409.79%, respectively. The liquid uptake ability 
in simulated enteric medium showed that all samples 
(except HPMCP) exhibited significantly higher %S 
values (p < 0.05) than those in simulated gastric medium. 
In addition, SD 1:15:15 exhibited the highest %S value 
(2074.44) followed by SD 1:10:10, SSG and HPMCP, in 
that order. Polymeric swelling is an important property of 
the mucoadhesion process because it contributes to the 
mobility and expansion of polymer chains. Both of these 
factors allow for polymer interpenetration with mucin. 
Liquid absorption is the first step in the relaxation and 
expansion of polymer chains that characterize swelling 
behavior. The high swelling values of SSG in both media 
can be attributed to the peculiar behavior of swellable 
superdisintegrant polymers, such as SSG, because 
their action mechanism is based on the rapid expansion 
of the polymer matrix after contact with the aqueous 
environment. This behavior causes the development of 
tension in delimited regions that causes the structure to 
break into small particles (Bele, Derle, 2012).
The %S values of SD 1:10:10 and SD 1:15:15 
demonstrated that the polymer concentration did not affect 
the liquid sorption ability of SDs (p > 0.05), while HPMCP 
can restrict it in acid medium due to its insolubility when 
the pH is low. Increased liquid uptake values in the 
simulated enteric medium indicated that increases in pH 
should favor carboxyl group repulsion in HPMCP, causing 
the chains to move farther apart loosening the polymer 
matrix. Both of these factors favor the entrance of water 
molecules (Oliveira et al., 2010).
According to Table II, the highest Wad value was 
exhibited by HPMCP while SSG and SD Wad values 
were similar (p > 0.05). Despite the high Wad values of 
HPMCP, its presence did not affect the adhesiveness of 
SD because the Wad values of SD 1:10:10 and 1:15:15 
were similar to SSG (p > 0.05). This indicated that this 
polymer determined this property of solid dispersions. 
The adhesiveness of polymeric systems is a very important 
property contributing to increased retention time and 
closer contact with mucous. These factors improve the 
permeability and bioavailability of drugs with typically 
poor bioavailability, such as AZT. The high adhesiveness 
of HPMCP (Table II) may be a result of interactions 
between the hydroxyl groups and mucin via non-
covalent secondary connections that build the hydrogen 
bonds. In addition, HPMCP is a swellable bioadhesive 
polymer derived from cellulose. Swelling enhances the 
adhesiveness of HPMCP through the interpenetration of 
the swollen polymer flexible chains in mucin (Andrews, 
Laverty, Jones, 2009). However, the Wad values of the SD 
samples examined in this study were similar to those of 
well-known adhesive polymers, such as carbopol 971P, 
polycarbophil AA1, sodium carboxymethylcellulose 
and carrageenan (Eouani et al., 2001), verifying their 
significant mucoadhesive properties. Despite the higher 
liquid sorption ability of SD in enteric medium when 
compared to HPMCP, the mucoadhesiveness of SD was 
TABLE I - Liquid uptake ability (%) of samples
Time 
(min)
Liquid Uptake Ability (%)
SSG HPMCP SD 1:10:10 SD 1:15:15
a b a b a b a b
5 511.08 
(± 76.90)
869.29 
(± 10.83)
208.59 
(± 21.25)
221.40 
(± 18.45)
247.07 
(± 38.57)
793.17 
(± 211.35)
287.46 
(± 21.18)
1015.23 
(± 109.90)
30 529.56 
(± 76.90)
875.55 
(± 21.66)
214.72 
(± 38.31)
258.30 
(± 18.45)
284.13 
(± 53.49)
1159.24 
(± 211.35)
311.93 
(± 18.34)
1269.04 
(± 109.90)
60 541.87 
(± 74.65)
894.31 
(± 21.66)
220.86 
(± 31.87)
270.60 
(± 21.30)
339.72 
(± 10.69)
1464.31 
(± 317.03)
348.62 
(± 18.34)
1649.75 
(± 109.90)
90 554.19 
(± 84.65)
919.32 
(± 18.76)
220.86 
(± 31.87)
295.20 
(± 18.45)
376.78 
(± 10.69)
1830.38 
(± 317.03)
385.32 
(± 18.34)
2030.46 
(± 109.90)
120 560.34 
(± 92.97)
938.09 
(± 18.76)
220.86 
(± 31.87)
313.65 
(± 18.45)
395.31 
(± 10.69)
2074.44 
(± 211.35)
409.79 
(± 10.59)
2284.26 
(± 190.35)
(a) simulated acid medium 0.1N HCl (pH 1.2); (b) simulated phosphate buffer (pH 7.4).
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lower than HPMCP. These results are consistent with 
findings regarding other crucial properties of adhesiveness 
in SD samples. In this sense, the SSG molecular weight 
could have contributed to steric hindrance that harmed the 
ability of swollen polymer flexible chains to interpenetrate 
into the mucin meshes of mucus, limiting the adhesiveness 
of SD samples (Lai, Wang, Hanes, 2009).
In acid medium, the AZT-free drug release profile 
(Figure 5) showed that approximately 50% of the drug 
was released in 15 minutes. On the other hand, SD 1:10:10 
and SD 1:15:15 released only 11% (± 0.0178) and 19% 
(± 0.0100) of the drug in 15 minutes, and 19% (± 0.0012) 
and 37% (± 0.0184) in 30 minutes, respectively. In 
enteric medium, the drug release profiles demonstrated 
that SD 1:10:10 was also able to release 81% (± 0.0716) 
of the drug at 60 minutes and SD 1:15:15 was able to 
release 80% (± 0.1097) in 90 minutes. The AZT-free 
drug release profile reached 80% in 45 minutes in acid 
medium (Figure 5) because it is highly soluble in this 
medium. SD 1:10:10 and SD 1:15:15 exhibited low drug 
release rates in acid media releasing 19% (± 0.0012) 
and 37% (± 0.0184) of drug, respectively in 30 min. 
This behavior can be attributed to the gastro-resistance 
properties of HPMCP, which exhibited lower swelling in 
this medium (Table 1), avoiding erosion and contributing 
to decreasing drug release rates (Oliveira et al., 2010). 
Indeed, it can be observed despite the presence of HPMCP, 
an enteric polymer, the drug release rates in the first 
15 minutes were very similar for both acid and enteric 
media. However, after 30 minutes, the drug release rates 
were higher in enteric than in acid medium, suggesting 
HPMCP dissolution. HPMCP dissolution increases the 
drug dissolution rate.
HPMCP is used in SDs to control drug release rates 
due to its insolubility in gastric fluid and its capacity to 
dissolve in the upper intestine at pH values higher than 5.5 
(Giri et al., 2012). The association of HPMCP with SSG, 
a polymer that quickly swells in aqueous medium, allows 
a swollen matrix to form that entraps the drug decreasing 
the drug release rate. The pH-dependence of HPMCP leads 
to polymeric hydration in the enteric medium, enabling the 
formation of water-filled pathways by which AZT can be 
released (Kim et al., 2007).
The intestinal permeability of free AZT, SD and 
PM (shown in Figure 6), was significantly higher in SD 
(65.2%) than in free AZT (33.9%) (p<0.05). The drug 
permeability was reduced in PM (45.5%); however, 
the permeability of PM did not differ significantly from 
other samples (p>0.05). The presence of VER, a P-gp 
blocker, improved the permeability of the free drug 
(43.5%) (p<0.05%); however, it did not influence SD drug 
permeability (69.7%, p>0.05%). In Figure 6, it is clear that 
the permeability of AZT carried in SD was significantly 
greater (69.6%) when compared to free AZT (33.9%) 
and PM (45.4%). This sharp increase in permeability of 
AZT carried in SD may be a result of the formation of 
a solid amorphous drug solution in the polymer matrix 
that modified the biological interaction improving its 
permeability.
The permeation values of PM (45.4%) were 
similar to those observed in free AZT in the presence of 
VER (43.5%). The presence of VER did not affect the 
permeation of SD (p>0.05). VER is a known P-gp inhibitor 
that blocks the efflux pump and improves AZT permeation 
(Quevedo et al., 2011). These findings alerted us to the 
similarities between the P-pg blocking effects of VER and 
carrier polymers.
The similarity difference between drug permeability 
from SD and PM (Figure 6) indicated that the drug 
amorphization (Figure 3) inherent to SD preparation did 
not affect this property. Based on this finding, carrier 
polymers are imperative for increasing permeability for 
TABLE II - Mucoadhesive performance of polymers and SDs
SAMPLE Wad (µJ)
SSG 1896 (±0.69)
HPMCP 3137 (±0.51)
SD 1:10:10 1507 (±0.25)
SD 1:15:15 1702 (±0.29)
FIGURE 5 - AZT release profiles from SD: (▲) AZT; (●) SD 
1:10:10, (■) SD 1:15:15 in simulated gastric medium; (○) SD 
1:10:10, (□) SD 1:15:15 in simulated enteric medium.
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the following reasons. First, the high liquid absorption 
ability of SD should allow a high degree of swelling 
in polymers, particularly of SSG, contributing to the 
mucoadhesion of the system. Closer contact between 
the drug and epithelium and a high local concentration 
gradient enhances AZT permeability. In addition, the 
high hydration capacity of polymers can lead to the 
accumulation of liquid around the intestinal membrane. 
This accumulation results in high hydrostatic pressure in 
the paracellular junctions, promoting their opening. Thus, 
the passage of drug through the intestinal membrane is 
favored and drug permeation is increased.
The influence of P-gp on AZT permeation was 
examined by examining the permeability of free AZT in 
the presence of VER, a known P-gp inhibitor. Addition 
of VER improved AZT permeation; however, the same 
trend was not observed in the SD samples, which were 
unaffected by VER (p>0.05). These findings pointed to 
the possibility that carrier polymers and VER exert similar 
influences by inhibiting the efflux pump via P-gp inhibition 
thereby improving AZT permeation.
In a recent study, Takizawa et al. (2013) investigated 
the influence of pharmaceutical excipients, such as 
microcrystalline cellulose (MCC), starch sodium glycolate 
(SSG), hydroxypropylmethyl cellulose (HPMC), ethyl 
cellulose (EC), and others on the membrane permeation 
of 5(6)-carboxyfluorescein (5-CF) in rat jejunum and 
ileum using the in vitro sac method. SSG significantly 
increased the membrane permeability of 5-CF in the 
jejunum, demonstrating that this polymer influences 
the intestinal efflux pump mechanism and enhances 
drug permeation. However, the membrane permeation-
enhancing mechanism has not yet been elucidated. 
Complementary studies will be necessary to determine the 
effects of pharmaceutical excipients on drug transport via 
paracellular and transcellular mechanisms and membrane 
transporters.
This interesting efflux pump inhibitor effect has also 
been reported in studies of several polymers, including 
Pluronic P85, Myrj 52 and chitosan-4-thiobutylamidine, 
polyethylene glycols, amphiphilic block copolymers, 
dendrimers, thiolated polymers, and dextran sulphate-
PLGA hybrid (Werle, 2008; Ling et al., 2010).
Jodoin, Demeule, Béliveau (2002) and Honda et al. 
(2004) also demonstrated that polyphenols of green tea and 
compounds of grapefruit juice represent natural polymeric 
efflux pump inhibitors. Carreno-Gomez and Duncan (2001) 
have patented the use of polysaccharides, dendrimers and 
surfactants as efflux pump inhibitors for the oral delivery 
of several drugs with low absorption. It has been revealed 
with experimental data that anionic gums (polysaccharides), 
dextran and sodium alginates possess the ability to inhibit 
efflux pumps.
According to the permeability data, the effects of 
SD carrier polymers on efflux pumps can be an additional 
important approach to be further exploited to improve the 
bioavailability of AZT.
CONCLUSION
DSC and XRD data demonstrated the amorphous 
state of drugs in SD and the lack of chemical interaction 
between drugs and carriers. The liquid uptake ability 
was sensitive to pH and was limited in acid medium 
because of HPMCP. The high adhesiveness of SDs was 
demonstrated, and steric hindrance seems to be a key 
factor in this process. The dissolution rates in acid medium 
were decreased probably due to the properties of HPMCP. 
Increases in polymer concentration contributed to the 
control of drug release rates. The intestinal permeability 
of AZT carried in SD was enhanced. The results indicated 
that the roles of polymer carriers and P-gp blockers are 
similar, improving this property. This study provides 
valuable insights for future experiments and provides a 
promising tool to increase the bioavailability of drugs.
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